J&J Offers To Help Shape Terms Of CMS Practical Clinical Trial Agenda
This article was originally published in The Gray Sheet
Executive Summary
Industry should work with CMS to establish a priority list to determine which technologies are best suited for practical clinical trials (PCTs), according to Johnson & Johnson VP-Health Policy & Government Affairs Kathy Buto
You may also be interested in...
PET/Alzheimer’s Study To Be First CMS-Funded Practical Clinical Trial – Tunis
CMS plans to release a position paper on new and ongoing initiatives related to improving the quality of clinical evidence, according to Chief Medical Officer Sean Tunis, MD
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.